

# Philadelphia Immunization Program

# Immunization Update



**August 3, 2015**

## New MenB Vaccines

The VFC Program now offers the two recently licensed meningococcal B vaccines, Bexsero<sup>®</sup>, manufactured by GlaxoSmithKline, and Trumenba<sup>®</sup>, manufactured by Pfizer Inc.

## Meningococcal Group B Vaccines (MenB)

Both Bexsero<sup>®</sup> and Trumenba<sup>®</sup> are recombinant vaccines licensed in the United States for prevention of meningococcal serotype B disease in indicated persons 10 – 25 years of age. Meningococcal disease is a life-threatening illness caused by bacteria that can cause sepsis and meningitis. Thirteen different meningococcal serogroups have been defined, five of which cause the great majority of disease (A, B, C, Y, and W135). According to the CDC, approximately 500 total cases of meningococcal disease were reported in the U.S. in 2012, of which 160 (32%) were caused by serogroup B. The majority of the other cases of meningococcal disease were caused by the serogroups A, C, Y, and W135. Invasive disease with these 4 serogroups are preventable by meningococcal conjugate quadrivalent vaccines (MCV4; Menactra<sup>®</sup>, Sanofi Pasteur; Menveo<sup>®</sup>, GlaxoSmithKline), which have been supplied by VFC for many years.

The Philadelphia VFC Program will supply either of the two vaccines to VFC providers – at their choice – for VFC-eligible, medically-indicated patients 10 – 18 years of age, as detailed below.

## Recommendations for Use of MenB Vaccines for VFC-Eligible Children

1. MenB should be administered to children 10 – 15 years of age at increased risk of meningococcal disease, due to one of the following:
  - Children 10 – 15 years of age with persistent complement component deficiencies;
  - Children 10 – 15 years of age with anatomic or functional asplenia;
  - Children 10 – 15 years of age at risk because of a serogroup B meningococcal outbreak.
2. MenB may be administered to children 16 – 18 years of age who are determined to be at increased risk of meningococcal type B disease

## Administration of MenB Vaccines

Bexsero<sup>®</sup> vaccine is licensed as a two-dose schedule, given at least 28 days apart, i.e., at 0 and 1 month. Trumenba<sup>®</sup> vaccine is licensed as a three-dose schedule, given at 0, 1 – 2 months, and 6 months. Both Bexsero<sup>®</sup> and Trumenba<sup>®</sup> are supplied in 0.5 mL prefilled syringes, to be administered via intramuscular injection into the deltoid muscle of the upper arm. If vaccine is administered at intervals longer than recommended, there is no need to restart the series. Each MenB vaccine can be administered at the same visit as all other indicated vaccines.

**Trumenba<sup>®</sup> CVX Code: 162**

**Trumenba<sup>®</sup> CPT Code: 90621**

**Bexsero<sup>®</sup> CVX Code: 163**

**Bexsero<sup>®</sup> CPT Code: 90620**